LENZ Therapeutics, Inc. (LENZ) Gains from Sales and Divestitures (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $703035.0 as the latest value for Q3 2023.
- On a quarterly basis, Gains from Sales and Divestitures rose 40.0% to $703035.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $703035.0, a 40.0% increase, with the full-year FY2022 number at $553443.0, changed N/A from a year prior.
- Gains from Sales and Divestitures was $703035.0 for Q3 2023 at LENZ Therapeutics, up from $653970.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $703035.0 in Q3 2023 to a low of $398028.0 in Q1 2022.